JK
Therapeutic Areas
Crinetics Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Paltusotine (CRN00808) | Acromegaly | Phase 3 |
| CRN04894 | Cushing's Disease | Phase 2 |
| CRN04777 | Hyperinsulinism | Phase 1 |
| CRN01941 | Neuroendocrine Tumors (NETs) | Preclinical |
Leadership Team at Crinetics Pharmaceuticals
RS
R. Scott Struthers, Ph.D.
Founder & Chief Executive Officer
SF
Stephen F. Betz, Ph.D.
Founder & Chief Scientific Officer
GA
Garlan Adams, J.D.
Chief Legal Officer
AC
Adriana C. Cabré
Chief Human Resources Officer
OH
Omar Hamdy, Ph.D.
Senior Vice President, Chief of Staff & Head of Portfolio Strategy
IK
Isabel Kalofonos
Chief Commercial Officer
JK
Jacqueline Kirby
Chief Corporate Affairs Officer
AS
Alan S. Krasner, M.D.
Chief Endocrinologist
CR
Chris Robillard
Chief Business Officer
TS
Tobin Schilke
Chief Financial Officer